Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 4Squamous Intraepithelial Lesions 4Uterine Cervical Dysplasia 2Anus Neoplasms 2Vulvar Neoplasms 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Vaginal Neoplasms 1Recurrence 1Penile Neoplasms 1Papillomavirus Infections 1Neoplasms 1Neoplasm Metastasis 1HIV Seropositivity 1Anal Canal Carcinoma 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 16Papillomavirus Vaccines 12Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 8Vaccines 5Human Papillomavirus DNA Tests 5Colposcopy 5Specimen Handling 4Blood Specimen Collection 4Watchful Waiting 3Vaginal Smears 3Patient Navigation 3Engerix-B 3Educational Status 3fludarabine phosphate 2fludarabine 2artesunic acid 2artemisinin 2aldesleukin 2Vaccines, Synthetic 2Standard of Care 2Practice Guidelines as Topic 2Polymerase Chain Reaction 2Mass Screening 2Light Coagulation 2Imiquimod 2Human Papillomavirus Recombinant Vaccine nonavalent 2GX-188 vaccine 2Early Intervention, Educational 2Data Collection 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Papillomavirus Infections × VGX-3100 × Gynecologic × Clear all
NCT00685412 2017-09-13

Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3

Inovio Pharmaceuticals

Phase 1 Completed
18 enrolled
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡